Group 1 - A-shares indices collectively strengthened on May 29, with the Hong Kong Stock Connect medical theme index leading the gains [1] - The Hong Kong medical ETF (159366) rose by 2.9%, with notable increases in constituent stocks such as WuXi AppTec up over 10%, MicroPort Medical up over 9%, and WuXi Biologics up over 8% [1] - The U.S. International Trade Court halted Trump's tariff policy, leading to significant gains in U.S. stock index futures, with the Dow Jones futures up nearly 500 points (1.1% increase) [1] Group 2 - At the 2025 ASCO annual meeting, Chinese pharmaceutical companies showcased strong performance in innovative drug fields, particularly in PD-1 bispecific antibodies, CAR-T, and ADC technologies [2] - Key focus areas include the technological accumulation and market expansion capabilities of leading innovative drug and medical device companies, especially those with core technologies and overseas licensing [2]

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown strong performance, with significant increases in constituent stocks, reflecting a robust trend in the healthcare sector in Hong Kong [3][5]. Group 1: Market Performance - As of May 29, 2025, the HSHCI rose by 1.59%, with notable gains from WuXi AppTec (7.47%), WuXi Biologics (6.84%), and WuXi PharmaTech (4.22%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.40%, with a recent price of 0.51 yuan, and has accumulated a 5.25% rise over the past two weeks [3]. - The ETF's trading volume reached 276 million yuan, with a turnover rate of 3.13% [3]. Group 2: Clinical Research and Innovation - The 2025 American Society of Clinical Oncology (ASCO) annual meeting will take place from May 30 to June 3, 2025, in Chicago, showcasing over 70 research studies from Chinese scholars [3]. - The inclusion of multiple domestic innovative drug studies at the ASCO conference indicates a thriving domestic pharmaceutical research environment, particularly in oncology [3]. Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF has a total size of 8.78 billion yuan, ranking in the top third among comparable funds [5]. - The ETF has seen a net value increase of 38.61% over the past year, ranking 16 out of 118 QDII equity funds [5]. - The ETF's highest monthly return since inception was 28.34%, with an average monthly return of 6.79% [5]. Group 4: Risk and Return Analysis - The ETF's Sharpe ratio for the past year is 1.27, indicating the highest return for a given level of risk among comparable funds [5]. - The ETF has experienced a relative drawdown of only 0.45% this year, the smallest among comparable funds [5]. Group 5: Valuation and Tracking Accuracy - The HSHCI's latest price-to-earnings ratio (PE-TTM) is 24.44, indicating a valuation lower than 90.15% of the past year [6]. - The ETF's tracking error over the past month is 0.022%, the highest tracking precision among comparable funds [6]. Group 6: Top Holdings - The top ten weighted stocks in the HSHCI account for 57.06% of the index, including companies like Innovent Biologics (4.44%) and WuXi Biologics (0.43%) [6][8].

Group 1 - The biotechnology sector in Hong Kong has seen a significant rally, with notable stock price increases for several companies [1] - WuXi AppTec (02126.HK) experienced an 11.7% increase in its stock price [1] - WuXi Biologics (02269.HK) and Junshi Biosciences (01877.HK) also saw substantial gains, with increases of 6.85% and nearly 6% respectively [1] - WuXi AppTec's subsidiary, WuXi Biologics (02268.HK), rose by 7.34% [1]

Group 1 - The Hong Kong stock market showed mixed performance, with the Hang Seng Index down 0.02% and the Hang Seng Tech Index up 0.19% [1] - The Hong Kong Innovative Drug ETF (159567) increased by 0.39%, with a turnover rate of 4.08% and a trading volume exceeding 660 million yuan, indicating active trading [1] - Notable stocks within the ETF included WuXi AppTec, which rose over 5%, WuXi Biologics, which increased over 4%, and Kelun Pharmaceutical, which gained over 2% [1] Group 2 - The innovative drug and AI medical sectors performed actively in Q1, with related fund products showing impressive returns, as the top-performing ETFs have all exceeded a 32% increase year-to-date [1] - The majority of pharmaceutical-themed funds have also shown positive growth, with 90% reporting positive performance for the year [1] - Industry analysts from Industrial Securities expect a steady recovery in the pharmaceutical sector due to favorable policies, particularly in the hospital market, which was previously impacted by anti-corruption and centralized procurement [1] Group 3 - Minsheng Securities highlighted continuous catalysts in the innovative drug sector, focusing on areas such as anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy, while also emphasizing the importance of domestic substitution and medical consumption, particularly in the beauty sector [2]

Core Viewpoint - The company is a global leader in ADC and bioconjugate drug CRDMO, with a significant market share and rapid growth in revenue and net profit driven by the ADC sector's expansion and its competitive advantages [1][2]. Group 1: Company Performance - The company achieved a global market share of 9.8% in 2022, ranking second globally and first domestically [1]. - From 2020 to 2023, the company's revenue and net profit CAGR were 180% and 121%, respectively, with projected growth rates of 91% and 277% in 2024 [1]. - The acceleration in net profit is attributed to the rapid development of the ADC sector and the unique competitive advantages of being an industry leader [1]. Group 2: ADC Market Outlook - The global ADC market is expected to exceed $13 billion in 2024, with six blockbuster drugs already launched [2]. - The market is projected to reach $64.7 billion by 2030, with a CAGR of 30.7% from 2024 to 2030, driven by advancements in treatment approaches and new drug approvals [2]. - The penetration rate of outsourced ADC R&D and production is 70%, significantly higher than the 34% for other biopharmaceuticals, indicating a high level of market activity [2]. Group 3: Service Platform Development - The company is developing a comprehensive one-stop service platform covering the entire process of bioconjugate drug development, including discovery, process development, and GMP production [2]. - The company has achieved one-stop production capabilities at its Wuxi base, significantly accelerating ADC project timelines from early discovery to BLA [2]. - The company plans to expand global production capacity, with a new facility in Singapore expected to be operational by the end of 2025 [2]. Group 4: Future Earnings Projections - Earnings per share are projected to be 1.05, 1.41, and 1.91 yuan for 2025, 2026, and 2027, respectively [3]. - Given the company's leadership in the global ADC CRDMO market and its rich project reserves, a DCF valuation method suggests a target price of HKD 47.81 [3].

Investment Rating - The report assigns a "Buy" rating for the company for the first time [1] Core Views - The company is a global leader in ADC and XDC CRDMO, benefiting from strong growth in the ADC sector and unique competitive advantages as an industry leader [5][20] - The ADC market is expected to grow significantly, with projections indicating a market size of $64.7 billion by 2030, driven by advancements in treatment strategies and new drug approvals [9][43] - The company is developing a comprehensive one-stop service platform that covers the entire process from discovery to GMP production, which is expected to accelerate project timelines and enhance growth potential [9][20] Financial Summary - The company’s revenue and net profit have shown rapid growth, with a CAGR of 180% and 121% from 2020 to 2023, respectively [20] - Revenue projections for 2025-2027 are estimated at HKD 5,470.58 million, HKD 7,169.95 million, and HKD 9,202.70 million, with corresponding net profits of HKD 1,257.14 million, HKD 1,695.86 million, and HKD 2,302.43 million [8][6] - The company’s gross margin is expected to improve from 26.35% in 2023 to 34.00% by 2027, while net margin is projected to rise from 13.35% to 25.02% over the same period [8] Market Position - The company holds a 9.8% global market share in the ADC sector, ranking second globally and first domestically, with a significant increase in overseas revenue contribution [68] - The ADC outsourcing service market is projected to grow from $1.5 billion in 2022 to over $11 billion by 2030, indicating a strong demand for the company's services [64][68]

Investment Rating - The report assigns a "Buy" rating for the company for the first time [1]. Core Views - The company is a global leader in ADC and XDC CRDMO, with a market share of 9.8% globally and ranked second worldwide, benefiting from the technological and capacity advantages of its major shareholders [5][68]. - The ADC market is experiencing rapid growth, with a projected CAGR of 30.7% from 2024 to 2030, driven by the increasing adoption of ADCs in cancer treatment [9][43]. - The company is expected to see significant revenue and profit growth, with a forecasted revenue of HKD 5,470.58 million in 2025, representing a 35% year-on-year increase [8]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of HKD 1.05, HKD 1.41, and HKD 1.91 for the years 2025, 2026, and 2027 respectively, indicating strong growth potential [6]. - The target price is set at HKD 47.81, based on DCF valuation, reflecting the company's leadership position in the ADC CRDMO sector and its robust project pipeline [6]. Company Overview - The company was established in 2013 and went public in 2023, focusing on the development and manufacturing of ADCs and XDCs [14]. - The core management team has extensive experience in the biopharmaceutical industry, enhancing the company's operational capabilities [18]. Revenue Growth and Profitability - The company has experienced a CAGR of 180% in revenue and 121% in net profit from 2020 to 2023, with a projected revenue growth of 91% and net profit growth of 277% in 2024 [20]. - The gross margin and net margin are expected to improve significantly due to enhanced operational efficiency and increased capacity utilization [23]. Market Dynamics - The ADC market is projected to reach USD 6.47 billion by 2030, with a significant shift towards frontline treatments and combination therapies with immunotherapy [43][48]. - The demand for ADC outsourcing services is expected to grow, with the global ADC outsourcing market projected to exceed USD 11 billion by 2030 [64].

Group 1 - The core viewpoint of the article is that招商证券 has initiated coverage on药明合联 with a "strong buy" rating, highlighting the company's growth potential in the future [1] - The report emphasizes that药明合联 has demonstrated significant advantages in technology and speed in both R&D and manufacturing [1] - The integrated CRDMO (Contract Research, Development, and Manufacturing Organization) advantage is expected to support the growth of leading enterprises and star projects, indicating a promising scaling opportunity in the market [1] Group 2 - The projected net profits for药明合联 are estimated to reach 1.44 billion, 1.88 billion, and 2.56 billion RMB for the years 2025, 2026, and 2027 respectively [1] - The report marks the first coverage of the stock by招商证券, reflecting a positive outlook on the company's future performance [1]

Investment Rating - The investment rating for WuXi AppTec (02268.HK) is "Outperform the Market" [6][4] Core Views - The company achieved impressive growth in 2024, with a main business revenue of 40.52 billion yuan (+90.8%) and a net profit attributable to shareholders of 10.70 billion yuan (+277.2%) [2][9] - The gross margin for 2024 was 30.6% (+4.3 percentage points), and the net profit margin was 26.4% (+13.3 percentage points), indicating a significant improvement in profitability [2][9] - The company has a strong order backlog of 9.91 billion USD (+71.2%) and has expanded its customer base to 499 clients (+44.5%), including 13 of the top 20 global pharmaceutical companies [2][17] Summary by Sections Financial Performance - In 2024, the company reported a main business revenue of 40.52 billion yuan, a 90.8% increase from the previous year, and a net profit of 10.70 billion yuan, reflecting a 277.2% growth [2][9] - Non-IFRS adjusted net profit reached 11.74 billion yuan, up 184.8% [2][9] - The company’s gross margin improved to 30.6%, and net profit margin increased to 26.4% [2][9] Order and Client Growth - The company’s order backlog reached 9.91 billion USD, marking a 71.2% increase [2][17] - The number of clients grew to 499, with a 44.5% increase, including 13 of the top 20 global pharmaceutical companies contributing 32.0% of revenue [2][17] Technological Advancements - The WuXiDARx™ technology has supported 45 preclinical candidates and 7 clinical projects, enhancing the company's capabilities in ADC and XDC drug services [3][21] - The company has completed 83 IND submissions for ADC and 2 for XDC, with 34 projects in late-stage clinical development [3][21] Capacity Expansion - The company is actively expanding its global production capacity, with new production lines in Wuxi and Shanghai expected to enhance service capabilities in the European and American markets [3][22] - The second production line in Wuxi is set to commence operations in November 2024, and further expansions are planned for 2025 and 2026 [3][22]

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of HKD 45.45 for the next six months [4][6][18]. Core Insights - The company achieved a revenue of CNY 4.052 billion in 2024, representing a year-on-year growth of 90.80%, and a net profit attributable to shareholders of CNY 1.070 billion, up 277.24% year-on-year [2][4]. - The growth is attributed to the continuous increase in ADC project numbers, the steady advancement of group projects to later stages, and improvements in operational efficiency [2][3]. - The company signed 53 new comprehensive projects in 2024, with an unfulfilled order amounting to USD 991 million, reflecting a 71% increase [3]. Revenue and Profit Forecast - The company is projected to achieve revenues of CNY 5.589 billion, CNY 7.433 billion, and CNY 9.515 billion for the years 2025 to 2027, with year-on-year growth rates of 37.93%, 32.98%, and 28.02% respectively [12][20]. - The net profit attributable to shareholders is expected to be CNY 1.371 billion, CNY 1.696 billion, and CNY 2.076 billion for the same years, with growth rates of 28.09%, 23.76%, and 22.41% respectively [12][20]. Valuation Analysis - The report indicates that the company's current price-to-earnings (PE) ratio is 29.76, which is close to its historical average [14][18]. - The estimated earnings per share (EPS) for 2025 is projected to be CNY 1.14, corresponding to a PE of 37 times [4][18]. - The report highlights that the company is well-positioned to benefit from the growing demand for ADC drug development and the high outsourcing rate in the industry [17].